Anavex Life Sciences Corp (AVXL)

[Talon38]

Biogen at the crossroads. There is no doubt that Biogen comprehends the gravity of the decision on what to to do with ANAVEX. With 2-73 being evaluated by their front line lab and remyelination determined, they sit at the crossroads of effective treatment and dare say cure for the most deadly neurodegenerative diseases such as Alzheimer's, M/S, Epilepsy, ALS, TBI, Rett Syndrome, Fragile X. Angelman's and possibly a host of other diseases responsive to Sigma 1 action. The ANAVEX pipeline is also rich in potential with 3-71 CNS power, the drugs with neurological pain and cancer applications.

With FDA trials being designed and the possibility that Janet Woodcock could apply the first "Master Protocol" for 2-73's development for a number of neurological diseases, the pressure is on Biogen to insure its goal to be the world's most important neuroscience company. They are faced with betting all their chips or having someone like Roche, BMS ,Pfizer Merck Novartis , GSK or Celegene up the ante.

Time will tell but the deeper we get in the trial process the more valuable we get

-----

Take another look at the Biogen Lab video, especially where Dr Sandrock talks about going for the cure and applying what is learned from M/S to other neurodegenerative diseases.

-----

Remyelination....Think what a drug that actually repairs nerve sheaths rather than just treating the disease symptoms would do to the M/S treatment world? It is the "Holy Grail".....Biogen knows this and its lab manager's, Drs Sandrock, Rudick, Ransohoff and Henderson have stated that in the Biogen Lab clip below, and ANAVEX knows it. Some of the other BPs may soon know what we have and will comprehend what a simple safe tablet form of 2-73 will due to M/S treatment cost. Last but most importantly the FDA and Congress will see a much more effective and cheaper drug to stop the spiraling costs of M/S disease.
-------

https://www.biogen.com/en_us/about-biogen/multiple-sclerosis/leading_a-path-forward.leading-way-ms.html